PT2563763E - Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida - Google Patents

Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida Download PDF

Info

Publication number
PT2563763E
PT2563763E PT11717917T PT11717917T PT2563763E PT 2563763 E PT2563763 E PT 2563763E PT 11717917 T PT11717917 T PT 11717917T PT 11717917 T PT11717917 T PT 11717917T PT 2563763 E PT2563763 E PT 2563763E
Authority
PT
Portugal
Prior art keywords
fluorofenyl
etoxy
chloropyridin
dihydropyridine
yloxy
Prior art date
Application number
PT11717917T
Other languages
English (en)
Portuguese (pt)
Inventor
Gretchen M Schroeder
Victor W Rosso
Dilbir S Bindra
Madhushree Yeshwant Gokhale
Cletus John Nunes
Ajit B Thakur
Xiaotian Yin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT2563763E publication Critical patent/PT2563763E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT11717917T 2010-04-30 2011-04-29 Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida PT2563763E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32971010P 2010-04-30 2010-04-30

Publications (1)

Publication Number Publication Date
PT2563763E true PT2563763E (pt) 2015-03-31

Family

ID=44209564

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11717917T PT2563763E (pt) 2010-04-30 2011-04-29 Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida

Country Status (17)

Country Link
US (2) US8911785B2 (enExample)
EP (1) EP2563763B1 (enExample)
JP (1) JP5820874B2 (enExample)
KR (1) KR101897302B1 (enExample)
CN (1) CN102971296B (enExample)
DK (1) DK2563763T3 (enExample)
ES (1) ES2533075T3 (enExample)
HR (1) HRP20150105T1 (enExample)
MY (1) MY183769A (enExample)
PH (1) PH12012502019A1 (enExample)
PL (1) PL2563763T3 (enExample)
PT (1) PT2563763E (enExample)
RS (1) RS53790B1 (enExample)
SG (1) SG184891A1 (enExample)
SI (1) SI2563763T1 (enExample)
SM (1) SMT201500069B (enExample)
WO (1) WO2011137274A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106635949B (zh) 2011-12-22 2020-05-19 生命技术公司 细胞培养基和方法
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
EP3911320A4 (en) * 2019-01-15 2022-11-30 The Translational Genomics Research Institute PHOSPHONATE CONJUGATES AND THEIR USES
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
TR200504775A1 (tr) 2005-11-30 2007-10-22 Esen Beki̇r Kendinden metal takviyeli pvc pencere ve kapı profilleri
US8865722B2 (en) * 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
MX2009004699A (es) * 2006-11-08 2009-05-15 Bristol Myers Squibb Co Compuestos de piridinona.
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2235001B1 (en) 2008-01-23 2014-12-24 Bristol-Myers Squibb Company Process for preparing pyridinone compounds

Also Published As

Publication number Publication date
JP5820874B2 (ja) 2015-11-24
SMT201500069B (it) 2015-05-05
EP2563763B1 (en) 2014-12-31
MY183769A (en) 2021-03-12
CN102971296A (zh) 2013-03-13
PL2563763T3 (pl) 2015-06-30
US8911785B2 (en) 2014-12-16
EP2563763A1 (en) 2013-03-06
WO2011137274A1 (en) 2011-11-03
US20130039989A1 (en) 2013-02-14
CN102971296B (zh) 2015-11-25
SG184891A1 (en) 2012-11-29
KR101897302B1 (ko) 2018-09-11
HRP20150105T1 (hr) 2015-03-13
ES2533075T3 (es) 2015-04-07
SI2563763T1 (sl) 2015-03-31
KR20130100237A (ko) 2013-09-10
JP2013525455A (ja) 2013-06-20
RS53790B1 (sr) 2015-06-30
PH12012502019A1 (en) 2017-08-18
US9233948B2 (en) 2016-01-12
DK2563763T3 (en) 2015-04-07
AU2011245269A1 (en) 2012-12-20
HK1179260A1 (en) 2013-09-27
US20150065719A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
LT2791160T (lt) Modifikuotos mrnr sudėtys
LT2817000T (lt) Peroralinės dabigatrano eteksilato farmacinės kompozicijos
FR2977490B1 (fr) Composition photoprotectrice
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
EP2709645A4 (en) ENHANCED PEPTIDE PHARMACEUTICAL AGENTS
BR112013012380A2 (pt) compostos 3-(aminoaril)-piridina
CO6930367A2 (es) Composiciones farmaceúticas
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
DE102011010827A8 (de) Verbesserte Patellapelotte
EP2663576A4 (en) NEW WNT COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF SUCH COMPOSITIONS
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
HUE037126T2 (hu) Immunogén készítmény
HUE040370T2 (hu) Gyógyszerkészítmények
EP2769718A4 (en) MEDICAL COMPOSITION
BR112013030897A2 (pt) composição.
FR2985007B1 (fr) Regenerateur.
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
IT1399446B1 (it) Macchina nastratrice.
BR112014032501A2 (pt) composto, e, composição farmacêutica.
BR112014028443A2 (pt) composição estéril.
DK2522105T3 (da) Genopretningsplan for fælles sti